Daiichi Sankyo’s FY2027 revenue exceeds consensus by 10%

Daiichi Sankyo’s revenue growth will outpace analyst estimates by at least 10%, driven by continued strong sales of its cancer drug portfolio, particularly Enhertu. This exceeds the consensus midpoint of $22.1B for FY2025.

Implied probability (Yes)

70%

Closes

2027-12-31